The National MS Society's National Medical Advisory Committee has issued its recommendations for MS disease-modifying therapies and the coronavirus (COVID-19), and we're sharing them in this episode.
You'll also hear about a new disease-modifying therapy that's about to receive FDA approval. We'll tell you about a clinical trial for a potential disease-modifying therapy for progressive MS that fell short of achieving its goals. And you'll hear about study results that indicate there are still a lot of people living with MS who aren't acting in their own best interest.
My guest this week is Dawnia Baynes. Besides being an MS Activist, Dawnia facilitates a very special MS support group, and last month, the Southern-California Nevada Chapter of the National MS Society named Dawnia their Inspirational Person of the Year.
The Coronavirus (COVID-19) and MS Disease-Modifying Therapies 2:41
Ozanimod scheduled for FDA Approval this Month 2:09
High-Dose Biotin For Progressive MS Fails to Improve Disability 7:41
Disease-Modifying Therapy Non-Compliance Among People Living with MS 9:07
My Interview with Dawnia Baynes 12:05
Share this Episode 24:26
Reminder…Please Donate to Walk-MS 24:46
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/133
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes.
Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Phone: (310) 526-2283
RealTalk MS Episode 133
Hosted By: Jon Strum
Guests: Dawnia Baynes
Tags: MS, MultipleSclerosis, MSResearch, MSActivist, MSSociety, Coronavirus, COVID-19, RealTalkMS